Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) had its price target reduced by Evercore ISI from $605.00 to $445.00 in a research note published on Thursday. They currently have an outperform rating on the biopharmaceutical company’s stock.

Other research analysts have also issued research reports about the company. UBS AG reiterated a buy rating and issued a $535.00 target price (up previously from $489.00) on shares of Regeneron Pharmaceuticals in a research report on Friday, August 4th. Citigroup Inc. lifted their target price on Regeneron Pharmaceuticals from $555.00 to $575.00 and gave the stock a buy rating in a research report on Friday, August 4th. Canaccord Genuity set a $522.00 target price on Regeneron Pharmaceuticals and gave the stock a buy rating in a research report on Thursday, August 3rd. Bank of America Corporation reiterated a buy rating and issued a $593.00 target price (up previously from $589.00) on shares of Regeneron Pharmaceuticals in a research report on Friday, July 21st. Finally, Credit Suisse Group reiterated a buy rating and issued a $485.00 target price on shares of Regeneron Pharmaceuticals in a research report on Monday, September 11th. Two research analysts have rated the stock with a sell rating, fifteen have given a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of Hold and an average price target of $475.34.

Regeneron Pharmaceuticals (NASDAQ REGN) traded down $3.10 during mid-day trading on Thursday, reaching $391.59. The company’s stock had a trading volume of 669,073 shares, compared to its average volume of 882,577. The company has a quick ratio of 3.07, a current ratio of 3.63 and a debt-to-equity ratio of 0.12. Regeneron Pharmaceuticals has a 52 week low of $340.09 and a 52 week high of $543.55. The stock has a market cap of $42,070.00, a P/E ratio of 33.32, a PEG ratio of 1.51 and a beta of 1.56.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported $3.99 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.83 by $0.16. The company had revenue of $1.50 billion for the quarter, compared to the consensus estimate of $1.45 billion. Regeneron Pharmaceuticals had a return on equity of 25.73% and a net margin of 23.17%. Regeneron Pharmaceuticals’s revenue for the quarter was up 23.0% compared to the same quarter last year. During the same period in the previous year, the business earned $3.13 EPS. equities research analysts anticipate that Regeneron Pharmaceuticals will post 13.55 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This piece of content was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another domain, it was illegally copied and reposted in violation of United States & international copyright legislation. The correct version of this piece of content can be read at https://www.thecerbatgem.com/2017/11/18/regeneron-pharmaceuticals-inc-regn-price-target-cut-to-445-00-by-analysts-at-evercore-isi.html.

In related news, major shareholder Sanofi bought 166,415 shares of the business’s stock in a transaction dated Thursday, August 24th. The shares were bought at an average cost of $480.93 per share, with a total value of $80,033,965.95. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Michael S. Brown sold 1,500 shares of the business’s stock in a transaction on Thursday, October 5th. The stock was sold at an average price of $475.00, for a total value of $712,500.00. The disclosure for this sale can be found here. Insiders sold a total of 61,460 shares of company stock worth $29,143,390 in the last three months. Company insiders own 10.80% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Oppenheimer & Co. Inc. grew its position in Regeneron Pharmaceuticals by 20.6% during the 2nd quarter. Oppenheimer & Co. Inc. now owns 7,007 shares of the biopharmaceutical company’s stock worth $3,441,000 after acquiring an additional 1,199 shares during the last quarter. Dupont Capital Management Corp bought a new stake in Regeneron Pharmaceuticals during the 2nd quarter worth approximately $220,000. Shell Asset Management Co. grew its position in Regeneron Pharmaceuticals by 24.1% during the 3rd quarter. Shell Asset Management Co. now owns 15,435 shares of the biopharmaceutical company’s stock worth $5,565,000 after acquiring an additional 2,999 shares during the last quarter. Blair William & Co. IL grew its position in Regeneron Pharmaceuticals by 4.8% during the 2nd quarter. Blair William & Co. IL now owns 1,713 shares of the biopharmaceutical company’s stock worth $841,000 after acquiring an additional 79 shares during the last quarter. Finally, Principal Financial Group Inc. grew its position in Regeneron Pharmaceuticals by 2.4% during the 2nd quarter. Principal Financial Group Inc. now owns 115,201 shares of the biopharmaceutical company’s stock worth $56,580,000 after acquiring an additional 2,646 shares during the last quarter. Institutional investors and hedge funds own 67.80% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Stock Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.